Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Baudax Bio Inc (BXRX)

Baudax Bio Inc (BXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030 FinancialNewsMedia - Fri Dec 30, 2022

EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END

NUWE : 1.0900 (-1.80%)
BXRX : 0.0218 (+7.39%)
KALA : 0.1151 (+2.68%)
HOTH : 0.7395 (+4.15%)
SILO : 0.4210 (-6.65%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030 PR Newswire - Fri Dec 30, 2022

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

NUWE : 1.0900 (-1.80%)
BXRX : 0.0218 (+7.39%)
KALA : 0.1151 (+2.68%)
HOTH : 0.7395 (+4.15%)
SILO : 0.4210 (-6.65%)
Baudax Bio (NASDAQ: BXRX) Launches Phase 2 Clinical Trial Testing BX1000 for Neuromuscular Blockade in Patients Undergoing Surgery Spotlight Growth - Fri Dec 9, 2022

Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use

BXRX : 0.0218 (+7.39%)
Wall Street - NYSE Full View
Pre-Market Brief: Stocks Move Higher Ahead of Key U.S. PPI Data Barchart - Fri Dec 9, 2022

December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices snapped a losing streak and closed higher on Thursday as market participants cheered a rise in...

LULU : 132.04 (+1.41%)
AVGO : 425.44 (-0.45%)
BXRX : 0.0218 (+7.39%)
JAZZ : 228.57 (+7.68%)
DOCU : 46.53 (-3.82%)
ESZ22 : 3,871.47s (-0.66%)
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights Globe Newswire - Thu Aug 11, 2022

ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I...

BXRX : 0.0218 (+7.39%)
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth Business Wire - Wed Jul 6, 2022

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership...

BXRX : 0.0218 (+7.39%)
Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference Globe Newswire - Wed May 18, 2022

MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care...

BXRX : 0.0218 (+7.39%)
Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Globe Newswire - Tue May 17, 2022

MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products...

BXRX : 0.0218 (+7.39%)

Barchart Exclusives

Time to Buy: This Cheap High-Yield Dividend Stock Is Trading Near Multi-Year Lows Barchart - 1 hour ago
Accenture's dividend yield is now over 3.6% thanks to the decline in its stock price. The stock's valuations have started to appear tempting at these levels, even though there are lingering concerns over AI being a risk to the company's business. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.